| Website | essexwoodlands.com |
| Phone | 650-543-1555 |
| Employees | |
| Founded | 1985 |
Essex Woodlands was founded in 1985 with the establishment of Essex Venture Fund I, LP. Since 1985, the Partnership has raised seven additional funds with nearly $2.5 billion under management, making Essex Woodlands one of the world’s largest and most established healthcare venture capital firms. The team is comprised of 23 professionals with principal offices in Palo Alto, Houston, New York and London. This team brings over 300 years of collective healthcare experience.
For over 20 years, the firm has maintained its dedicated focus to diversified healthcare investing—primarily serving as lead investor in the founding or the critical financings of over 100 healthcare companies in pharmaceutical, biotechnology, medical device, services and information technology sectors. In addition to its long-standing commitment to early stage companies, the firm has over a decade of experience as a leading late-stage healthcare investor, which includes mature venture, growth equity and PIPE investment opportunities.
| Company | Date | Round | Size | Participants |
| Entellus Medical | 11/09 | Series D | $30M | 3 |
| Complete Genomics | 8/09 | Series D | $45M | 6 |
| Oraya Therapeutics | 7/09 | Series C | $42M | 4 |
| Xanodyne | 6/09 | Series D | $38M | 7 |
| Chroma Therapeutics | 6/09 | Unattributed | $24.5M | 6 |
| Symphogen | 2/09 | Unattributed | €33M | 1 |
| Catalyst Biosciences | 12/08 | Series C | $40M | 7 |
| Nellix | 3/08 | Series C | $6.5M | 2 |
| Accumetrics | 2/08 | Series D | $28.8M | 7 |
| Oraya Therapeutics | 1/08 | Series B | $18M | 2 |
| Oraya Therapeutics | 6/07 | Series A | $4M | 1 |
| StrataGent Life Sciences | 5/07 | Series B | $16M | 2 |
| NeoVista | 12/06 | Series C | $41M | 6 |
